Inflammation Reduction by TREhalose AdminisTration
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Arterial wall inflammation has been consistently suggested to serve a causal role in
promoting atherosclerosis and predisposing to hard cardiovascular outcomes. Therefore, there
is a global trend in the pharmaceutical industry to develop safe and effective
anti-inflammatory agents that could lessen arterial wall inflammation and prevent its
detrimental impact on atheroma growth and instability. To this end, autophagy has emerged as
a key regulator of inflammation and dysfunctional autophagy machinery has been consistently
reported as a contributing factor to atherosclerosis and inflammation. Trehalose, a natural
disaccharide sugar found extensively among miscellaneous organisms, by preventing protein
denaturation plays various protective roles against stress conditions. Numerous studies
indicated trehalose's ability to induce macrophage autophagy-lysosomal biogenesis and reduce
inflammation. Also, intravenous (IV) administration of trehalose showed beneficial effects in
the reversal of atherosclerosis in atherosclerotic animals. Therefore, in this study, the
investigators will explore the potential efficacy of IV trehalose administration on arterial
inflammation by employing an positron emission tomography (PET) with 18F-labeled
fluoro-2-deoxyglucose (18F-FDG) and computed tomography (18F-FDG PET/CT) technique which
noninvasively characterizes vascular inflammation and atherosclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Mashhad University of Medical Sciences
Collaborators:
Mashhad Razavi Hospital National Institute for Medical Research Development